Global Artificial Insemination Market – Industry Trends and Forecast to 2029

Market Analysis and Size

In recent years, the artificial insemination market is anticipated to grow rapidly during the forecast period. According to a study published in the journal PLOS Medicine in 2012, around 48.5 million couples throughout the world were unable to have a child in 2010. Home-use kits, such as ovulation kits, pregnancy detection kits, and insemination devices, are frequently offered by market companies. Artificial insemination is a medical procedure that involves the purposeful injection of sperm into a female's uterus without the use of sexual intercourse. The most extensively used type of artificial insemination is intrauterine insemination (IUI). The rising prevalence of infertility is a major element driving the artificial insemination market forward.

Data Bridge Market Research analyses that the artificial insemination market was valued at USD 2,198.75 million in 2021 and is expected to reach USD 4099.98 million by 2029, registering a CAGR of 8.10% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

 Artificial insemination is a form of assisted reproduction in which a female's fallopian tubes, cervix, or uterus are injected with sperm that are still alive. It's done by quick and painless artificial insemination homologous (AIH) or artificial insemination donor semen (AID) procedures.  Artificial insemination is now utilized generally in animal breeding to improve reproductive success and conserve rare and endangered species. It also helps to avoid the spread of illnesses and sterility in animals caused by genital problems.

Report Scope and Market Segmentation

Artificial Insemination Market Dynamics

Drivers

• Increasing incidence of infertility

Infertility affects nearly 20 million women, according to the National Women's Health Resource Center. Total fertility is anticipated to decline from 2.43 to 2.39 (children per woman) between 2020 and 2030, according to the 2017 United Nations World Population Prospects report. The growing incidences of infertility among the world's population is propelling the artificial insemination market forward.

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of artificial insemination market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

Furthermore, the rising preference of modern women on Planned Parenthood because of uninterrupted full time professional career will influence the growth of artificial insemination market. Along with this, increasing urbanization and rising level of disposable income are the driving factors accelerating the growth of the artificial insemination market. Also, changing lifestyle of people and rising awareness among individuals about alternative reproductive treatments are the major market drivers that will further escalate the growth of artificial insemination market.

Opportunities

• Increase in strategic collaborations and new product launches      

Moreover, the market's growth is fueled by an increase in the number of new product launch and strategic collaboration of leading market players. This will provide beneficial opportunities for the artificial insemination market growth.

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the artificial insemination market growth during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with artificial insemination will obstruct the growth rate of market. The dearth of skilled professionals and lack of awareness will challenge the artificial insemination market. Additionally, impact of COVID-19 on supply chain and strict regulatory issues will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This artificial insemination market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the artificial insemination market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Artificial Insemination Market

Since its emergence in December 2019, the COVID-19  virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in the pneumonia cases. This virus spread quickly over the world, killing a large number of people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in a number of nations had imposed nationwide lockdowns in order to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world were having difficulty continuing their supply chain activities. The artificial insemination market was hampered by the supply chain slowness.

Global Artificial Insemination Market Scope

The artificial insemination market is segmented on the basis of type, product type, source type and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Intrauterine Insemination
• Intracervical Insemination
• Intravaginal Insemination
• Intratubal Insemination

Product Type

• Insemination Kits
• Home Conception Devices
• Accessories

Source Type

• AIH-Husband
• AID-Donor

End- User

• Hospitals
• Fertility Clinics
• Clinics
• Others

Artificial Insemination Market Regional Analysis/Insights

The artificial insemination market is analysed and market size insights and trends are provided by country, type, product type, source type and end-user as referenced above.

The countries covered in the artificial insemination market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the artificial insemination market because of the well-established healthcare infrastructure and technological advancement in this region. Additionally, presence of major key players and favourable rules and regulations will flourish the market’s growth rate in this region. 

Asia-Pacific is expected to grow during the forecast period due to rising prevalence of infertility among the populace and development of healthcare sector this region. Also, less stringent regulations will flourish the market’s growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The artificial insemination market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for artificial insemination market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the artificial insemination market. The data is available for historic period 2010-2020.

Competitive Landscape and Artificial Insemination Market Share Analysis

The Artificial insemination market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to artificial insemination market.

Some of the major players operating in the artificial insemination market are:

• Conceivex, Inc. (US)
• Pride Angel (UK)
• FUJIFILM Irvine Scientific (US)
• High-Tech Solutions (US)
• Rinovum Women's Health, LLC (US)
• TenderNeeds Fertility (US)
• Biogenics Inc. (US)
• LABOTECT GMBH (Germany)
• Hamilton Thorne, Inc (US)
• Nikon Instruments Inc. (US)
• Zander scientific Inc. (US)
• Surelife Pte Ltd. (Singapore)
• Genea Limited (Australia)
• Kitazato Corporation (Japan)
• Rocket Medical plc (UK)
• Vitrolife (Sweden)

SKU-68170